Mairs & Power Inc. Sells 24,718 Shares of Medtronic PLC $MDT

Mairs & Power Inc. reduced its holdings in Medtronic PLC (NYSE:MDT) by 5.4% during the 3rd quarter, HoldingsChannel.com reports. The institutional investor owned 430,572 shares of the medical technology company’s stock after selling 24,718 shares during the period. Mairs & Power Inc.’s holdings in Medtronic were worth $41,005,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors have also recently bought and sold shares of MDT. Brighton Jones LLC grew its position in Medtronic by 1,368.0% during the fourth quarter. Brighton Jones LLC now owns 39,989 shares of the medical technology company’s stock worth $3,194,000 after buying an additional 37,265 shares in the last quarter. Sivia Capital Partners LLC raised its holdings in Medtronic by 9.6% in the 2nd quarter. Sivia Capital Partners LLC now owns 4,356 shares of the medical technology company’s stock valued at $380,000 after acquiring an additional 381 shares in the last quarter. Cetera Investment Advisers lifted its position in shares of Medtronic by 1.7% in the 2nd quarter. Cetera Investment Advisers now owns 449,507 shares of the medical technology company’s stock worth $39,184,000 after acquiring an additional 7,481 shares during the period. Avantax Advisory Services Inc. grew its holdings in shares of Medtronic by 4.4% during the 2nd quarter. Avantax Advisory Services Inc. now owns 152,823 shares of the medical technology company’s stock worth $13,322,000 after purchasing an additional 6,391 shares in the last quarter. Finally, Citizens Financial Group Inc. RI grew its holdings in shares of Medtronic by 102.1% during the 2nd quarter. Citizens Financial Group Inc. RI now owns 30,303 shares of the medical technology company’s stock worth $2,642,000 after purchasing an additional 15,307 shares in the last quarter. 82.06% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Medtronic

In other news, EVP Harry Skip Kiil sold 52,524 shares of Medtronic stock in a transaction that occurred on Thursday, February 19th. The shares were sold at an average price of $97.71, for a total value of $5,132,120.04. Following the completion of the transaction, the executive vice president owned 32,768 shares in the company, valued at approximately $3,201,761.28. The trade was a 61.58% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders own 0.26% of the company’s stock.

Wall Street Analysts Forecast Growth

MDT has been the topic of a number of research reports. UBS Group restated a “neutral” rating and set a $104.00 price objective on shares of Medtronic in a research report on Wednesday, February 4th. The Goldman Sachs Group set a $111.00 price target on shares of Medtronic and gave the stock a “neutral” rating in a research note on Wednesday, November 19th. Leerink Partners reaffirmed an “outperform” rating and set a $119.00 price objective on shares of Medtronic in a report on Tuesday, March 10th. Robert W. Baird lowered their target price on shares of Medtronic from $103.00 to $100.00 and set a “neutral” rating on the stock in a research note on Wednesday, February 18th. Finally, CICC Research started coverage on shares of Medtronic in a research note on Friday, January 30th. They set an “outperform” rating for the company. One research analyst has rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and ten have issued a Hold rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $110.74.

Medtronic Stock Up 1.1%

Shares of NYSE MDT opened at $88.13 on Tuesday. Medtronic PLC has a 52-week low of $79.55 and a 52-week high of $106.33. The company has a debt-to-equity ratio of 0.57, a quick ratio of 1.87 and a current ratio of 2.54. The business has a fifty day moving average of $97.77 and a two-hundred day moving average of $96.88. The stock has a market cap of $113.15 billion, a PE ratio of 24.55, a PEG ratio of 2.24 and a beta of 0.71.

Medtronic (NYSE:MDT) last posted its earnings results on Tuesday, February 17th. The medical technology company reported $1.36 earnings per share for the quarter, topping the consensus estimate of $1.34 by $0.02. The business had revenue of $9.02 billion for the quarter, compared to analyst estimates of $8.89 billion. Medtronic had a net margin of 13.00% and a return on equity of 14.82%. The firm’s quarterly revenue was up 5.8% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $1.38 EPS. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. As a group, equities research analysts expect that Medtronic PLC will post 5.46 earnings per share for the current fiscal year.

Medtronic Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, April 17th. Shareholders of record on Friday, March 27th will be paid a dividend of $0.71 per share. This represents a $2.84 annualized dividend and a yield of 3.2%. The ex-dividend date of this dividend is Friday, March 27th. Medtronic’s dividend payout ratio is currently 79.11%.

Medtronic Profile

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).